Citation

Altamura AC, Bobo WV, Meltzer HY. Int. Clin. Psychopharmacol. 2007; 22(5): 249-267.

Affiliation

Department of Psychiatry, University of Milan, Hospital Luigi Sacco, Via G.B. Grassi 74, 20157 Milan, Italy. c.altamura@hsacco.it

Copyright

(Copyright © 2007, Lippincott Williams and Wilkins)

DOI

10.1097/YIC.0b013e3280de2c7f

PMID

17690594

Abstract

A major focus of current treatment research in schizophrenia is the determinants of long-term outcome, including functional outcome and general medical well being, rather than just specific domains of psychopathology such as positive and negative symptoms, mood symptoms, and cognitive impairment. This focus does not negate the importance of the latter issues but sees them as factors contributing to long-term outcome to variable extents. A long-term treatment focus facilitates a more clinically relevant assessment of benefits versus risks of available treatments. For instance, atypical antipsychotic drugs as a group have clear advantages for several important domains of efficacy that may influence long-term outcome, but are also more expensive over the long term. Use of some agents may also result in deleterious physical health consequences as well as large additional costs over the long term owing to metabolic adverse effects. The present paper focuses on several key issues in schizophrenia which are important determinants of long-term outcome in schizophrenia, or influence choice of antipsychotic drugs, or both, including: (i) duration of untreated psychosis; (ii) impact of relapse on long-term outcome; (iii) limited efficacy for specific domains of psychopathology of current treatments; (iv) mortality owing to suicide; and (v) mortality owing to other causes (e.g. cardiovascular disease).

Language: en